Welcome to our dedicated page for Biomarin Pharmaceutical SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioMarin Pharmaceutical Inc. (BMRN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed rare disease biotechnology company, BioMarin files periodic and current reports that describe its financial condition, results of operations, governance changes and material corporate events.
Investors researching BMRN can review Forms 10-K and 10-Q for detailed discussions of BioMarin’s business, risk factors, rare disease portfolio and pipeline strategy. Current reports on Form 8-K, such as those announcing quarterly results, acquisitions, leadership changes or guidance updates, give insight into significant developments affecting the company’s Enzyme Therapies, Skeletal Conditions and gene therapy franchises.
Through this page, users can also track information that may appear in proxy materials and other filings, including board composition and committee appointments, executive roles and the company’s use of non-GAAP financial measures like Non-GAAP Operating Margin and Non-GAAP Diluted EPS, as described in its disclosures. For those monitoring corporate actions, merger agreements, or business development transactions, the related 8-K filings and exhibits are a primary source of official information.
Stock Titan enhances these filings with AI-powered summaries that explain key points in plain language, helping readers interpret long or technical documents. Real-time updates from EDGAR, combined with structured access to forms such as 10-K, 10-Q and 8-K, allow investors to follow BioMarin’s regulatory reporting history and understand how management communicates strategy, performance and risk to the market.
Guyer Charles Greg reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical executive Charles Greg Guyer, EVP and Chief Technical Officer, reported three equity awards credited on February 25, 2026. The awards represent performance-based restricted stock units earned for results over 2023–2025 tied to relative total shareholder return, development goals, and core operating margin, vesting on March 15, 2026 if he remains in service.
BIOMARIN PHARMACEUTICAL INC executive Gregory R. Friberg, EVP and Chief R&D Officer, reported an open-market sale of 6,326 shares of common stock on February 26, 2026. The shares were sold at a weighted average price of $60.3758 per share, with individual sale prices ranging from $60.36 to $60.51 according to the footnote. After this transaction, Friberg directly holds 37,578 shares of BioMarin common stock.
BioMarin Pharmaceutical EVP and Chief Legal Officer George Eric Davis reported both stock sales and equity awards. On
On
BioMarin Pharmaceutical executive Brian Mueller received multiple performance-based stock awards. On
These shares come from Restricted Stock Units earned for performance over 2023–2025, based on relative total shareholder return, development goals, and core operating margin. The earned RSUs convert into common stock on a 1:1 basis and are scheduled to vest on
BioMarin Pharmaceutical Inc. notice of proposed sale of common stock on a Form 144 through a broker-dealer. The filing lists Fidelity Brokerage Services LLC and references proposed transactions tied to restricted stock vesting on
BioMarin Pharmaceutical reports 2025 total revenues of
The company agreed in December 2025 to acquire Amicus Therapeutics for
BioMarin is exiting ROCTAVIAN after lower‑than‑anticipated commercial opportunities, recording about
BioMarin Pharmaceutical (BMRN) filed a Form 144 reporting a proposed sale of common stock by Fidelity Brokerage Services LLC. The notice lists multiple lots tied to prior acquisitions, including 1,474 shares from a stock option exercise (02/24/2023), 317 shares from an ESPP purchase (04/30/2023), 301 shares from an ESPP purchase (04/30/2024), and 23,969 shares from restricted stock vesting (03/15/2025).
BioMarin Pharmaceutical reported strong growth for 2025 and set higher profit goals for 2026 while reshaping its portfolio. Total revenues rose 13% to
Full‑year GAAP net income was
BioMarin announced a definitive agreement to acquire Amicus Therapeutics, adding Galafold and Pombiliti + Opfolda, and has secured about
BioMarin Pharmaceutical Inc. has closed a private offering of
BioMarin plans to use the net proceeds, together with a new
Offering proceeds are held in escrow until the Amicus acquisition closes. If the deal is not completed on or before
BioMarin Pharmaceutical Inc. is raising debt financing to help fund its pending acquisition of Amicus Therapeutics. The company agreed to sell $850 million of 5.500% senior unsecured notes due 2034 in a private offering to qualified institutional buyers and non‑U.S. persons.
BioMarin also completed syndication of a new $2 billion senior secured term loan B facility, in addition to a previously arranged $800 million senior secured term loan A facility, and expects to enter into a $600 million senior secured revolving credit facility. It plans to use net proceeds from the notes, together with borrowings under the term facilities and cash on hand, to pay the Acquisition consideration and related fees and expenses. If the Acquisition is not completed by December 19, 2026, BioMarin must redeem the notes at 100% of their initial issue price plus accrued interest.